Survodutide is an investigational GLP-1 and glucagon receptor agonist designed to reduce hunger and affect body weight, energy use and liver fat.
What Survodutide does and why that matters
Survodutide combines two hormone signals. Its GLP-1 action is intended to reduce hunger, increase fullness and improve blood-sugar control. Its glucagon action is intended to affect energy use and fat handling in the liver. In practical terms, researchers are testing whether this combination can reduce body weight and liver fat. It remains investigational, so those goals are not approved treatment claims. [1,2]
Function evidence: Two hormone targets with human trial evidence
What participants experienced in trials
The intended experience is less hunger, earlier fullness and, over time, clinically meaningful weight loss. SYNCHRONIZE-1 provides human phase 3 evidence for the weight change rather than relying on a hormone theory alone. At week 76, the treatment-regimen estimand showed mean losses of 12.2% with 3.6 mg and 13.0% with 6.0 mg, compared with 5.4% on placebo. The efficacy estimand produced larger numbers because it answers a different question about treatment adherence. Survodutide remains investigational, so these are trial findings rather than approved-use promises. [1,2,3]
What supports this description: Randomized phase 3 weight outcomes; investigational product
Survodutide Dosing status
Dose: No consumer dose is established or recommended here. | Frequency: No routine treatment schedule established. | Cycle: No validated consumer cycle. | Route: No routine patient route established.
Preparation: No patient reconstitution recipe. Trial preparation is not a recommendation..
Survodutide is still being studied and is not an approved treatment. In SYNCHRONIZE-1, researchers tested 3.6 mg and 6.0 mg once weekly. The 4.8 mg figure comes from an earlier Phase 2 trial. At week 76, mean weight change under the treatment-regimen estimand was a 12.2% decrease and a 13.0% decrease, compared with a 5.4% decrease for placebo. [1,2]
Survodutide Effects
Phase 3 weight change. In SYNCHRONIZE-1, mean weight at week 76 decreased by 12.2% with 3.6 mg and 13.0% with 6.0 mg under the treatment-regimen estimand. The placebo decrease was 5.4%. Results under the efficacy estimand were larger because it asks a different question about adherence. [1]
Survodutide Side Effects
Gastrointestinal adverse events. Published rates for gastrointestinal adverse events were 80.9% at 3.6 mg, 89.7% at 6.0 mg, and 47.9% with placebo. These are trial-arm rates, not a prediction for an individual. [1]
Investigational status. Survodutide is not FDA-approved. Trial doses describe a research protocol and are not a consumer titration or reconstitution plan. [1,3]
Frequently Asked Questions About Survodutide
Which doses did SYNCHRONIZE-1 test?
The Phase 3 trial tested maintenance doses of 3.6 mg and 6.0 mg once weekly. The 4.8 mg figure belongs to Phase 2 and should not be presented as the Phase 3 maximum. [1,2]
What is the difference between the estimands?
The efficacy estimand estimates results under continued assigned treatment without prohibited rescue therapy; the treatment-regimen estimand reflects outcomes regardless of adherence or rescue treatment. They answer different questions and should not be mixed. [1]
Evidence
Published Phase 3 obesity trial; still investigational. Survodutide is still being studied and is not an approved treatment. In SYNCHRONIZE-1, researchers tested 3.6 mg and 6.0 mg once weekly. The 4.8 mg figure comes from an earlier Phase 2 trial. At week 76, mean weight change under the treatment-regimen estimand was a 12.2% decrease and a 13.0% decrease, compared with a 5.4% decrease for placebo. [1,2]
le Roux CW, et al. Once-Weekly Survodutide in Adults with Obesity N Engl J Med, 2026. PMID 42253238
Blüher M, et al. Once-weekly survodutide in people with obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial Lancet Diabetes Endocrinol, 2024. PMID 38330987
Educational evidence summary. Approval applies only to the named product and indication; compounded, investigational, and research-market products are different categories.
◇An FDA-approved label or a patient-specific prescription from a licensed pharmacy
◇The active ingredient, strength, dosage form, concentration, lot, and dispensing instructions
◇Identity or purity tests only support the tests performed; they do not prove sterility, endotoxin safety, dose accuracy, stability, or clinical suitability
◇A “research use only” vial is not a patient medicine
